Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Cancer, Non-Small Cell: early-phase trial registry
7 of 17 indexed Lung Cancer, Non-Small Cell trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 7 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Lung Cancer, Non-Small Cell: 17 US clinical trials tracked, 7 recruiting.
Lung Cancer, Non-Small Cell is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 5 of these trials.
Enrollment posture brief
Registry condition lung-cancer-non-small-cell
OPEN 7 | RECR 41% | LATE 4 | EARLY 7 | RANK #1004 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)
Lung Cancer, Non-Small Cell lists 7 open slots (41% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Cancer, Non-Small Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Cancer, Non-Small Cell is recruiting below its size-band peers.
7 of 17 indexed trials (41.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lung Cancer, Non-Small Cell research.
GlaxoSmithKline accounts for 5 of 17 trials (29.4%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Lung Cancer, Non-Small Cell enrolment sits around 194 participants.
Median target enrolment is 194 among the 17 trials that report a genuine target (sentinel values excluded). 7 of those (41.2%) plan for fewer than 100 participants.
-
Lung Cancer, Non-Small Cell research is mostly interventional.
13 interventional and 4 observational studies make up this index (76.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NCT05537922
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics
NCT04510129
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Krystal Biotech
NCT06228326
Engagement of Veterans With Lung Cancer
Palo Alto Veterans Institute for Research
NCT07219251
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
NCT07145255
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Abramson Cancer Center at Penn Medicine
NCT04691817
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
Our Lady of the Lake Hospital
NCT06659458
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
GlaxoSmithKline
NCT04655976
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
GlaxoSmithKline
NCT04475939
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
GlaxoSmithKline
NCT05565378
NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer
Tufts University
NCT04986670
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
GlaxoSmithKline
NCT06472076
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03377023
IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
IO Biotech
NCT05077709
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
Wake Forest University Health Sciences
NCT05415358
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
GlaxoSmithKline
NCT00390806
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen
NCT03245736
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Cancer, Non-Small Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Cancer, Non-Small Cell trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Cancer, Non-Small Cell page
17 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Lung Cancer, Non-Small Cell trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GlaxoSmithKline sponsors the most Lung Cancer, Non-Small Cell trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Cancer, Non-Small Cell condition card totals 17 registered trials; most-linked intervention Dostarlimab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.